XML 56 R36.htm IDEA: XBRL DOCUMENT
v3.24.0.1

SIGNIFICANT ACCOUNTING POLICIES (General) (Details) |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 29, 2022 | Jul. 02, 2021 USD ($) $ / shares shares | May 13, 2021 USD ($) | Feb. 17, 2021 USD ($) shares | May 31, 2023 USD ($) | Jul. 23, 2018 USD ($) | Oct. 19, 2017 USD ($) | Oct. 31, 2015 | Mar. 31, 2023 USD ($) shares | Dec. 31, 2023 USD ($) item agreement $ / shares shares | Dec. 31, 2023 USD ($) item agreement $ / shares shares | Dec. 31, 2022 USD ($) $ / shares shares | Dec. 31, 2021 USD ($) shares | Mar. 21, 2023 item | Feb. 27, 2023 USD ($) | Aug. 25, 2021
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of global licensing and supply agreements | agreement |  |  |  |  |  |  |  |  |  | 2 | 2 |  |  |  |  |
Number of patients dosed | item |  |  |  |  |  |  |  |  |  |  |  |  |  | 56 |  |
Number of shares issued (in shares) | shares |  |  |  | 8,749,999 |  |  |  |  |  |  |  |  |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  |  |  |  |  |  |  |  |  | $ 0.001 | $ 0.001 | $ 0.001 |  |  |  |
Stock issuance proceeds |  |  |  | $ 40,200,000 |  |  |  |  |  |  | $ 23,954,000 | $ 8,236,000 | $ 8,575,000 |  |  |
Amount of milestone payment received |  |  |  |  | $ 20,000,000.0 |  |  |  |  |  |  |  |  |  |  |
Aggregate principal amount |  |  |  |  |  |  |  |  |  | $ 20,251,000 | 20,251,000 | 0 |  |  |  |
Accumulated deficit |  |  |  |  |  |  |  |  |  | (381,549,000) | (381,549,000) | $ (389,861,000) |  |  |  |
Present value of operating lease liabilities |  |  |  |  |  |  |  |  |  | $ 6,030,000 | $ 6,030,000 |  |  |  |  |
Equity component of convertible notes, net of transaction costs |  |  |  |  |  |  |  |  |  |  |  |  | $ 12,027,000 |  |  |
ATM Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  |  |  |  |  |  |  |  | 13,980,060 | 0 | 12,560,150 | 7,473,038 |  |  |  |
Common Stock, Par or Stated Value Per Share | $ / shares |  | $ 0.001 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of stock, maximum offering price |  | $ 20,000,000.0 |  |  |  |  |  |  |  | $ 6,400,000 | $ 6,400,000 |  |  |  | $ 20,000,000.0 |
Stock issuance proceeds |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  | $ 24,900,000 | $ 8,700,000 |  |  |  |
ATM Equity Offering Sales Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares issued (in shares) | shares |  | 3,296,123 |  |  |  |  |  |  |  |  |  |  | 1,867,552 |  |  |
Stock issuance proceeds |  | $ 13,800,000 |  |  |  |  |  |  |  |  |  |  | $ 8,800,000 |  |  |
2021 Notes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  |  |  | 7.50% | 7.50% |  |  |  |  |
2024 Notes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate (as a percent) |  |  |  |  |  |  |  |  |  | 7.50% | 7.50% |  |  |  |  | 7.50%
Minimum cash balance required |  |  |  |  |  |  |  |  |  | $ 7,500,000 | $ 7,500,000 |  |  |  |  |
Transactions costs in connection with the exchange of convertible notes |  |  |  |  |  |  |  |  |  |  | 869,000 |  |  |  |  |
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement Revenues and Expenses Sharing Percentage |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |
Chiesi Agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable payment receivable |  |  |  |  |  | $ 25,000,000.0 | $ 25,000,000.0 |  |  | 50,000,000.0 | 50,000,000.0 |  |  |  |  |
Extended term of agreement | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agreement amendment payment receivable |  |  |  |  |  |  |  |  |  | $ 30,000,000.0 | 30,000,000.0 |  |  |  |  |
Amount of milestone payment received |  |  |  |  |  |  |  |  |  |  | $ 20,000,000.0 |  |  |  |  |
Revenue, Performance Obligation, Number | item |  |  |  |  |  |  |  |  |  | 2 | 2 |  |  |  |  |
Chiesi US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  |  |  |  |  | 20,000,000.0 |  |  |  |  |  |  |  |  |  |
Maximum entitlement of development costs to cover per year |  |  |  |  |  | 7,500,000 |  |  |  |  |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  |  |  |  | $ 760,000,000.0 |  |  |  | $ 735,000,000.0 | $ 735,000,000.0 |  |  |  |  |
Chiesi US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  |  |  | 15.00% |  |  |  |  | 15.00% |  |  |  |  |
Chiesi US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  |  |  | 40.00% |  |  |  |  | 40.00% |  |  |  |  |
Chiesi Ex-US Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amounts payable to cover development costs |  |  |  |  |  |  | 25,000,000.0 |  |  |  |  |  |  |  |  |
Maximum entitlement of development costs to cover per year |  |  |  |  |  |  | 10,000,000.0 |  |  |  |  |  |  |  |  |
Agreement amendment payment receivable |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Change in amount receivable for achievement of regulatory and commercial milestones |  |  | $ 25,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Additional amount payable for achievement of regulatory and commercial milestones |  |  |  |  |  |  | $ 320,000,000.0 |  |  |  |  |  |  |  |  |
Chiesi Ex-US Agreement | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  |  |  |  | 15.00% |  |  |  | 15.00% |  |  |  |  |
Chiesi Ex-US Agreement | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment on net sales percentage |  |  |  |  |  |  | 35.00% |  |  |  | 35.00% |  |  |  |  |
Fill/Finish Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extended term of agreement | 7 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The total amount payable to entity for the achievement of regulatory and commercial milestones. + References No definition available. + Details
Name: | plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to the entity to cover development costs under agreement. + References No definition available. + Details
Name: | plx_AdditionalAmountsPayableToCoverDevelopmentCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Agreement Amendment Payment Receivable + References No definition available. + Details
Name: | plx_AgreementAmendmentPaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones + References No definition available. + Details
Name: | plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement revenues and expense sharing percentage. + References No definition available. + Details
Name: | plx_CollaborativeArrangementRevenuesExpensesSharingPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The transaction costs in connection with exchange of convertible notes. + References No definition available. + Details
Name: | plx_DebtConversionTransactionCostsInConnectionWithExchangeOfConvertibleDebt
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity Component Of Convertible Notes Net Of Transaction Costs + References No definition available. + Details
Name: | plx_EquityComponentOfConvertibleNotesNetOfTransactionCosts
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Extended term of agreement. + References No definition available. + Details
Name: | plx_ExtendedTermOfAgreement
Namespace Prefix: | plx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum cash balance required to be maintained under long term debt agreements. + References No definition available. + Details
Name: | plx_MaintainOfMinimumCashBalance
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum amount payable to entity to cover development costs in any year under agreement. + References No definition available. + Details
Name: | plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of milestone payment received upon achievement of certain milestone. + References No definition available. + Details
Name: | plx_MilestonePaymentReceived
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the number of global licensing and supply agreements. + References No definition available. + Details
Name: | plx_NumberOfGlobalLicensingAndSupplyAgreements
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of patients that were dosed in the trial. + References No definition available. + Details
Name: | plx_NumberOfPatientsDosed
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the payment as a percentage of future net sales. + References No definition available. + Details
Name: | plx_PaymentOnNetSalesPercentage
Namespace Prefix: | plx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Performance Obligation, Number + References No definition available. + Details
Name: | plx_RevenuePerformanceObligationNumber
Namespace Prefix: | plx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Sale of stock, maximum offering price. + References No definition available. + Details
Name: | plx_SaleOfStockMaximumOfferingPrice
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | plx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | plx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights. + References No definition available. + Details
Name: | plx_UpfrontNonrefundableNoncreditablePaymentReceivable
Namespace Prefix: | plx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Face amount or stated value per share of common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_ConvertibleDebtCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Present value of lessee's discounted obligation for lease payments from operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details
Name: | us-gaap_OperatingLeaseLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of accumulated undistributed earnings (deficit). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_RetainedEarningsAccumulatedDeficit
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=plx_AtmEquityOfferingSalesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_BR
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=plx_FillFinishAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |